Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other Operating Expenses for 5 consecutive years, with $24.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 84.28% to $24.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.1 million, a 800.67% increase, with the full-year FY2025 number at $56.1 million, up 800.82% from a year prior.
  • Other Operating Expenses was $24.4 million for Q4 2025 at Madrigal Pharmaceuticals, down from $481.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $481.1 million in Q3 2025 to a low of -$453.9 million in Q2 2025.